[Form 4] Thermo Fisher Scientific, Inc. Insider Trading Activity
Marc N. Casper, Chairman & CEO of Thermo Fisher Scientific (TMO), reported option exercise and market sales on 09/05/2025 under a Rule 10b5-1 plan. The filing shows the exercise or acquisition of 400 shares at an exercise/conversion price of $253.99 and three market dispositions of 200, 100 and 100 shares at $500, $501 and $501.01 respectively.
Beneficial ownership reported after the transactions is 113,762.285 shares. The report discloses indirect holdings of 11,300 shares by the Alison Casper 2020 Irrevocable Trust, 14,608 shares by Floral Park Associates, Inc., and 5,000 shares by MNC 2020 Irrevocable Trust. The transactions were effected pursuant to a 10b5-1 trading plan adopted April 28, 2025.
Marc N. Casper, Presidente e CEO di Thermo Fisher Scientific (TMO), ha dichiarato l'esercizio di opzioni e vendite sul mercato il 09/05/2025 nell'ambito di un piano Rule 10b5-1. La comunicazione indica l'esercizio o l'acquisto di 400 azioni a un prezzo di esercizio/conversione di $253,99 e tre cessioni sul mercato di 200, 100 e 100 azioni rispettivamente a $500, $501 e $501,01.
La partecipazione beneficiaria riportata dopo le transazioni è di 113.762,285 azioni. Il rapporto segnala detenzioni indirette di 11.300 azioni dall'Alison Casper 2020 Irrevocable Trust, 14.608 azioni da Floral Park Associates, Inc. e 5.000 azioni dal MNC 2020 Irrevocable Trust. Le transazioni sono state effettuate ai sensi di un piano di negoziazione 10b5-1 adottato il 28 aprile 2025.
Marc N. Casper, Presidente y CEO de Thermo Fisher Scientific (TMO), reportó el ejercicio de opciones y ventas en el mercado el 09/05/2025 bajo un plan Rule 10b5-1. La presentación muestra el ejercicio o adquisición de 400 acciones a un precio de ejercicio/conversión de $253.99 y tres disposiciones en el mercado de 200, 100 y 100 acciones a $500, $501 y $501.01, respectivamente.
La titularidad beneficiaria informada tras las transacciones es de 113,762.285 acciones. El informe revela participaciones indirectas de 11,300 acciones por Alison Casper 2020 Irrevocable Trust, 14,608 acciones por Floral Park Associates, Inc., y 5,000 acciones por MNC 2020 Irrevocable Trust. Las transacciones se realizaron conforme a un plan de negociación 10b5-1 adoptado el 28 de abril de 2025.
Thermo Fisher Scientific(TMO)� 회장 � CEO� Marc N. Casper� 2025� 09/05� Rule 10b5-1 계획� 따라 옵션 행사 � 시장 매도� 보고했습니다. 제출서류에는 행사/취득� 400주가 행사/전환가 $253.99� 기재되어 있으�, 시장 처분은 각각 $500, $501, $501.01� 200�, 100�, 100주로 보고되어 있습니다.
거래 � 보고� 실소� 지분은 113,762.285주입니다. 보고서에� Alison Casper 2020 Irrevocable Trust� 간접 보유 11,300�, Floral Park Associates, Inc.� 14,608�, MNC 2020 Irrevocable Trust� 5,000주가 공시되어 있습니다. 해당 거래들은 2025� 4� 28� 채택� 10b5-1 거래 계획� 따라 이루어졌습니�.
Marc N. Casper, président et CEO de Thermo Fisher Scientific (TMO), a déclaré l'exercice d'options et des ventes sur le marché le 09/05/2025 dans le cadre d'un plan Rule 10b5-1. Le dépôt indique l'exercice ou l'acquisition de 400 actions à un prix d'exercice/de conversion de 253,99 $ et trois cessions sur le marché de 200, 100 et 100 actions aux prix respectifs de 500 $, 501 $ et 501,01 $.
La détention bénéficiaire déclarée après les opérations s'élève à 113 762,285 actions. Le rapport divulgue des participations indirectes de 11 300 actions par l'Alison Casper 2020 Irrevocable Trust, 14 608 actions par Floral Park Associates, Inc. et 5 000 actions par le MNC 2020 Irrevocable Trust. Les opérations ont été effectuées conformément à un plan de négociation 10b5-1 adopté le 28 avril 2025.
Marc N. Casper, Vorsitzender und CEO von Thermo Fisher Scientific (TMO), meldete am 09.05.2025 die Ausübung von Optionen und Verkäufe am Markt im Rahmen eines Rule-10b5-1-Plans. Die Einreichung zeigt die Ausübung oder den Erwerb von 400 Aktien zu einem Ausübungs-/Umwandlungspreis von $253,99 sowie drei Marktveräußerungen von 200, 100 und 100 Aktien zu jeweils $500, $501 und $501,01.
Das nach den Transaktionen gemeldete wirtschaftliche Eigentum beträgt 113.762,285 Aktien. Der Bericht legt indirekte Bestände von 11.300 Aktien durch den Alison Casper 2020 Irrevocable Trust, 14.608 Aktien durch Floral Park Associates, Inc. und 5.000 Aktien durch den MNC 2020 Irrevocable Trust offen. Die Transaktionen erfolgten gemäß einem am 28. April 2025 angenommenen 10b5-1-Handelsplan.
- Transactions executed under a Rule 10b5-1 plan, indicating preplanned trading and compliance with insider trading rules
- Maintained substantial beneficial ownership after the transactions: 113,762.285 shares reported
- Clear disclosure of indirect holdings by trusts and entities (Alison Casper 2020 Irrevocable Trust, Floral Park Associates, Inc., MNC 2020 Irrevocable Trust)
- Net decrease of 400 shares in reported beneficial ownership following the reported exercise and sales (from 114,162.285 to 113,762.285)
- Market dispositions at higher prices (sales at $500, $501, $501.01) reduced direct holdings
Insights
TL;DR: Routine insider activity—option exercise plus planned market sales under a 10b5-1 plan; modest net decrease in reported holdings.
The filing documents an option-related acquisition of 400 shares at $253.99 and three market sales totaling 400 shares at roughly $500�$501.01 on 09/05/2025. The transactions were executed under a Rule 10b5-1 plan adopted on April 28, 2025, indicating preplanned disposition rather than opportunistic trading. Reported beneficial ownership after the activity is 113,762.285 shares, including specified indirect holdings. From an investor-materiality standpoint, these are routine executive transactions and do not by themselves change control or signal a material shift in ownership.
TL;DR: Governance signals consistent with compliance—use of 10b5-1 plan and attorney-in-fact signature are clear procedural safeguards.
The disclosure notes the 10b5-1 plan adoption date and includes an attorney-in-fact signature dated 09/09/2025, reflecting governance procedures for insider transactions. The filer also disclaims indirect beneficial ownership for certain trust-held shares except for pecuniary interests. These elements align with standard disclosure practice for executive stock exercises and planned sales.
Marc N. Casper, Presidente e CEO di Thermo Fisher Scientific (TMO), ha dichiarato l'esercizio di opzioni e vendite sul mercato il 09/05/2025 nell'ambito di un piano Rule 10b5-1. La comunicazione indica l'esercizio o l'acquisto di 400 azioni a un prezzo di esercizio/conversione di $253,99 e tre cessioni sul mercato di 200, 100 e 100 azioni rispettivamente a $500, $501 e $501,01.
La partecipazione beneficiaria riportata dopo le transazioni è di 113.762,285 azioni. Il rapporto segnala detenzioni indirette di 11.300 azioni dall'Alison Casper 2020 Irrevocable Trust, 14.608 azioni da Floral Park Associates, Inc. e 5.000 azioni dal MNC 2020 Irrevocable Trust. Le transazioni sono state effettuate ai sensi di un piano di negoziazione 10b5-1 adottato il 28 aprile 2025.
Marc N. Casper, Presidente y CEO de Thermo Fisher Scientific (TMO), reportó el ejercicio de opciones y ventas en el mercado el 09/05/2025 bajo un plan Rule 10b5-1. La presentación muestra el ejercicio o adquisición de 400 acciones a un precio de ejercicio/conversión de $253.99 y tres disposiciones en el mercado de 200, 100 y 100 acciones a $500, $501 y $501.01, respectivamente.
La titularidad beneficiaria informada tras las transacciones es de 113,762.285 acciones. El informe revela participaciones indirectas de 11,300 acciones por Alison Casper 2020 Irrevocable Trust, 14,608 acciones por Floral Park Associates, Inc., y 5,000 acciones por MNC 2020 Irrevocable Trust. Las transacciones se realizaron conforme a un plan de negociación 10b5-1 adoptado el 28 de abril de 2025.
Thermo Fisher Scientific(TMO)� 회장 � CEO� Marc N. Casper� 2025� 09/05� Rule 10b5-1 계획� 따라 옵션 행사 � 시장 매도� 보고했습니다. 제출서류에는 행사/취득� 400주가 행사/전환가 $253.99� 기재되어 있으�, 시장 처분은 각각 $500, $501, $501.01� 200�, 100�, 100주로 보고되어 있습니다.
거래 � 보고� 실소� 지분은 113,762.285주입니다. 보고서에� Alison Casper 2020 Irrevocable Trust� 간접 보유 11,300�, Floral Park Associates, Inc.� 14,608�, MNC 2020 Irrevocable Trust� 5,000주가 공시되어 있습니다. 해당 거래들은 2025� 4� 28� 채택� 10b5-1 거래 계획� 따라 이루어졌습니�.
Marc N. Casper, président et CEO de Thermo Fisher Scientific (TMO), a déclaré l'exercice d'options et des ventes sur le marché le 09/05/2025 dans le cadre d'un plan Rule 10b5-1. Le dépôt indique l'exercice ou l'acquisition de 400 actions à un prix d'exercice/de conversion de 253,99 $ et trois cessions sur le marché de 200, 100 et 100 actions aux prix respectifs de 500 $, 501 $ et 501,01 $.
La détention bénéficiaire déclarée après les opérations s'élève à 113 762,285 actions. Le rapport divulgue des participations indirectes de 11 300 actions par l'Alison Casper 2020 Irrevocable Trust, 14 608 actions par Floral Park Associates, Inc. et 5 000 actions par le MNC 2020 Irrevocable Trust. Les opérations ont été effectuées conformément à un plan de négociation 10b5-1 adopté le 28 avril 2025.
Marc N. Casper, Vorsitzender und CEO von Thermo Fisher Scientific (TMO), meldete am 09.05.2025 die Ausübung von Optionen und Verkäufe am Markt im Rahmen eines Rule-10b5-1-Plans. Die Einreichung zeigt die Ausübung oder den Erwerb von 400 Aktien zu einem Ausübungs-/Umwandlungspreis von $253,99 sowie drei Marktveräußerungen von 200, 100 und 100 Aktien zu jeweils $500, $501 und $501,01.
Das nach den Transaktionen gemeldete wirtschaftliche Eigentum beträgt 113.762,285 Aktien. Der Bericht legt indirekte Bestände von 11.300 Aktien durch den Alison Casper 2020 Irrevocable Trust, 14.608 Aktien durch Floral Park Associates, Inc. und 5.000 Aktien durch den MNC 2020 Irrevocable Trust offen. Die Transaktionen erfolgten gemäß einem am 28. April 2025 angenommenen 10b5-1-Handelsplan.